- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human…
Updating the Human Brain With Vital NeuroMANHATTAN, NY / ACCESSWIRE / February 17, 2024 / As the world continues to…
TORONTO, ON / ACCESSWIRE / February 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”),…
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add…
Chimeric Bait Receptors for Combatting Brain Cancers and Neurodegenerative Diseases Can Be Delivered via Programmed Microglial CellsLONDON, UK / ACCESSWIRE…
On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning…
Non-opioid drug candidate from Tonix lowered pain and also improved sleep and fatigueLatest Phase 3 trial achieved primary endpoint (p=0.00005)Potential…
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and…
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel…